|Tuberculosis is an infection, mostly of the respiratory tract, by the bacteria Mycobacterium tuberculosis.
It is a pathogenic bacterial species in the family Mycobacteriaceae and the causative agent of most cases of tuberculosis. It has an unusual, waxy coating on its cell surface, which makes the cells impervious to Gram staining.
Depending on the body systems affected by the disease, TB may cause fever, weight loss, fatigue, cough, chest pain and shortness of breath.
The Quantiferon-TB Gold test, is a blood test for specific TB antigens. It is produced by Celestis and is much more useful in the diagnosis of tuberculosis.
Both tests are unaffected by previous BCG vaccination, but attract medical benefits in Australia only when the patient is immunocompromised
The control of TB is managed by a combination of – public health measures, – early and intense chemotherapy of new cases (especially cases in contact with HIV, the young, those with malignancies, etc.) and – immunisation of certain groups.
Nearly all new TB cases seen in Australia are in foreign born persons, so there is a high probability of airline travel in a patient during six to twelve months of TB treatment. Guidelines have been published in Victoria in an attempt to minimise the risk of transmission of TB to other passengers, as well as continuity of anti-TB treatment for the patient.
Australia has a low incidence of TB, especially when compared with neighbouring S.E.Asian countries, but about 1000 cases are notified each year, mainly in immigrants from those countries.
Victorian statutory requirement
Infection and death rates vary around the world. However, every second, someone is infected with M.tuberculosis and every 18 seconds someone in the world dies from TB.
Globally, incidence rates peaked at 143 (range, 136–151) cases per 100 000 population in 2004.
According to the World Health Organization (WHO), 8.8 million new cases of tuberculosis (TB) were reported globally in 2005 – 7.4 million were in Asia and sub-Saharan Africa.
The number of notified cases of TB in 2008 was 5.7 million, equivalent to 55–67% of all incident cases, with a best estimate of 61% (10% less than the Global Plan milestone of a case detection rate of 71% in 2008). The targets for tuberculosis control, framed within the United Nations Millennium Development Goals, are to ensure that the incidence per head of tuberculosis is falling by 2015, and that the 1990 prevalence and mortality per head are halved by 2015.
Globally, the gulf between prevalence and mortality rates in 2008 and the target levels in African countries make it unlikely that 1990 prevalence and death rates will be halved by 2015 for the world as a whole.
The risk to the usual tourist or short-time traveller is generally very low. Risk is dictated by the destination, accommodation, living conditions and hygiene. Please discuss with your GoodTrips doctor.
Tuberculosis on aircraft
Available evidence indicates that the risk of transmission of M.tuberculosis on board aircraft is low and limited to persons in close contact with an infectious case for 8 hours or longer. In 2008, WHO released its third edition of Guidelines for Prevention and Control.
Certain groups most affected
After years of declining numbers in developed countries, TB is now on the rise in certain groups such as the homeless, users of illicit drugs and those infected with HIV. In the West, immigrant groups account for the majority of new cases of TB. Its global re-emergence in the early 1990s has been somewhat reversed over the last few years, although the decline is still slow in Africa and Eastern Europe, with the countries of the former Soviet Union still shouldering a considerable burden of the disease (80% of the estimated 444,777 cases in Europe in 2004, and the highest treatment failure rate (7%) in the world). In 2005, 426,717 tuberculosis cases were notified in Europe, 72% by 12 ex-republics of the former Soviet Union. The Baltic countries (Latvia, Lithuania and Estonia) have TB rates which are many times higher than in the Nordic countries.
England, Wales and Northern Ireland have also failed to follow the overall declining trend. Between 2004 and 2005, TB incidence in the UK increased by 11%, while in 2006 the rate grew by 2%, reaching 14.8 per 10,000 population (mainly in Asian-born people living in London).
In 2007, South Africa, with 0·7% of the world’s population, had 17% of the global burden of HIV infection, and one of the world’s worst tuberculosis epidemics, compounded by rising drug resistance and HIV co-infection.
– a new lethality –
A recent WHO report stated: “HIV and TB form a lethal combination, each speeding the other’s progress. HIV weakens the immune system. TB is a leading cause of death among people who are HIV-positive … and … accounts for about 13% of AIDS deaths worldwide.”
From WER 3 March 2006: The Stop TB Partnership has developed a global plan to stop TB, utilising the combined resources of governments, donors, NGOs and other organisations during the period 2006-2015. New diagnostic tests, new drug treatments and a new effective vaccine are all expected to be developed during this period. Estimated cost is US$56 billion.
Strenuous efforts are now being made to ‘stop the scourge of TB, which was once considered conquered. A major complication in the chemotherapy of TB has been the development of drug resistance, particularly in some third world countries.
Extensively drug-resistant TB
CDC defines extensively-drug resistant TB as strains resistant to isoniazid, rifampin, any fluoroquinolone and at least one second-line injectable drug, including amikacin, kanamycin or capreomycin.
Defined as TB resistant at least to isoniazid (INH) and rifampicin (RMP), the two most powerful first-line anti-TB drugs.
Almost 30 000 cases of multidrug-resistant TB (MDR-TB) were notified in 2008; this is 11% of the total number of cases of MDR-TB estimated to exist among cases notified in 2008.
Since the 1980s, multi drug-resistant TB (MDR-TB) has increased in many countries around the world, especially in China and Russia.
In the US. 202,436 culture-confirmed TB cases were reported in the period 1993- 2006. Those which were extensively drug-resistant (XDR TB) increased from 3% in 2000 to 11% in 2004.
In a recent South African study, patients with TB/HIV coinfection showed an incidence of 41% MDR-TB.
In Europe, MDR-TB is strongly associated with origin from the former Soviet Union. Surveys suggest a widespread problem in Eastern countries (for example, 15% total MDR-TB in Georgia in 2005-2006 and 25% in Kazakhstan in 2001, regardless of prior treatment).
The first cases of completely drug-resistant and fatal TB have been reported from Italy and Germany, both in young women.
Bacillus Calmette–Guérin (BCG) vaccine is a live strain of modified M bovis and is used in Australia in certain groups only:
– Aboriginal neonates living in regions of high incidence,
– neonates of patients with TB or leprosy,
– children under 5 travelling to countries of high TB prevalence,
– children less than 16 years, who are exposed to an individual with active pulmonary TB and who cannot be treated with isoniazid.
– healthcare workers (rules differ between the states).
Albert Calmette and Camille Guérin achieved the first genuine success in immunisation against tuberculosis in 1906, using attenuated bovine-strain tuberculosis, called Bacille Calmette–Guérin (BCG). The BCG vaccine was first used on humans in 1921 in France, but received widespread acceptance in the US, Great Britain, and Germany only after World War II.
Although the protective value of BCG vaccine against pulmonary disease in adults ranges from little to none it has been shown to persist for 50 to 60 years, suggesting that a single dose of an effective BCG vaccine can have a long duration of protection.
Mantoux testing (see above) uses a purified protein derivative (PPD) of a broth containing tubercle bacilli, called old tuberculin, which is injected intradermally into the forearm. The reaction is read after 2-3 days and an assessment of prior exposure is sometimes made.
From The New England Journal of Medicine
Viable BCG is one of the most widely used vaccines to control tuberculosis. Administered as a single shot to newborns, it prevents severe disease and reduces mortality among children, but it does not protect against pulmonary tuberculosis in children or adults. With 9 million new, mostly pulmonary cases and nearly 2 million deaths from tuberculosis each year, there is a great need for improved vaccines against this devastating disease.
Tuberculosis has been present in humans since the neolithic period, but not recognised as a single disease until the 1820s. The bacillus causing tuberculosis, M. tuberculosis, was identified and described on 1882 by Robert Koch, who received a Nobel Prize for his discovery.
Tuberculosis also affects cattle and infected milk may pass the disease to humans. The risk of transmission from this source was dramatically reduced by the invention of the pasteurisation process, by the French scientist, Louis Pasteur, in 1864.
The evolution of tuberculosis has produced bacteria resistant to all known antibiotics. It seems very likely that vaccines are the only long-term hope for millions of humans.
In the USA, the first human trials of a genetically engineered vaccine (rBCG30) have taken place.
In India, a vaccine using a live strain of Mycobacterium habana is under development.
British researchers have had excellent results from a new vaccine, called MVA85A, which has proved safe and effective during phase I clinical testing, especially when used in conjunction with BCG vaccine.
In South Korea a DNA-based vaccine is being developed.
An effective vaccine against TB is desperately needed.